BiologicalDrug
Aldesleukin clinical trials
Also written Proleukin.
Includes 8 studies of Low-dose Aldesleukin ILT-101.
How each study uses aldesleukin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the aldesleukin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 May 1992 · PROLEUKIN · BLA 103293 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
159 studies that test it; most in 2015 (12); 2 more planned to start later
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1992 | 1 |
| 1995 | 4 |
| 1996 | 4 |
| 1997 | 6 |
| 1998 | 8 |
| 1999 | 2 |
| 2000 | 5 |
| 2001 | 5 |
| 2002 | 5 |
| 2003 | 1 |
| 2004 | 4 |
| 2005 | 8 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 7 |
| 2014 | 7 |
| 2015 | 12 |
| 2016 | 2 |
| 2017 | 11 |
| 2018 | 4 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 162
National Cancer Institute (NCI) (33) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · Fred Hutchinson Cancer Center (11) · M.D. Anderson Cancer Center (8) · Assistance Publique - Hôpitaux de Paris (8) · Chiron Corporation (5) · Jonsson Comprehensive Cancer Center (4) · Masonic Cancer Center, University of Minnesota (4)
Often tested with
Tested in the same studies.
Cyclophosphamide (32) · Fludarabine (26) · Fludarabine phosphate (12) · Busulfan (5) · Interleukin-2 (5) · Melphalan (4) · Sargramostim (4) · Etoposide (4)
Related medicines
As reviewed, each with the page that says it.
- A recombinant medicine of Interleukin-2 source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9
Studies that test aldesleukin.
- Nov 2026Gene and Vaccine Therapy in Treating Patients With Advanced MalignanciesPhase 2 · Jonsson Comprehensive Cancer Center
- Jan 2027Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerEarly Phase 1 · Emory University
- Apr 2027Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal MetastasisPhase 1 · Mayo Clinic
- Jun 2027Low Dose IL-2 for the Treatment of Crohn's DiseasePhase 1/2 · Boston Children's Hospital
- Sep 2027Adding IL-2 to Tebentafusp to Eradicate Cancer ProgressionPhase 1/2 · St Vincent's Hospital, Sydney
- Oct 2027T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerPhase 2 · National Cancer Institute (NCI)
- Oct 2027Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV MelanomaPhase 1 · M.D. Anderson Cancer Center
- Nov 2027Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 DiabetesPhase 2 · Assistance Publique - Hôpitaux de Paris
- Nov 2027Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological TumorsPhase 2 · The First Affiliated Hospital of Xiamen University
Studies
Open first, then newest update. How each study uses aldesleukin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 174
- Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT05155033Written as Aldesleukin
- Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerNot yet recruitingPhase 2Beth Israel Deaconess Medical CenterNCT07925333Written as Aldesleukin (IL-2)
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingPhase 1National Cancer Institute (NCI)NCT06904066Written as aldesleukin
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingPhase 1/2National Cancer Institute (NCI)NCT02830724Written as Aldesleukin
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingPhase 2National Cancer Institute (NCI)NCT02133196Written as Aldesleukin
- Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal TumorsNot yet recruitingPhase 2Joal BeaneNCT07647068Written as Aldesleukin
- Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 DiabetesRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT05153070Written as ILT101
- Low Dose IL-2 for the Treatment of Crohn's DiseaseRecruitingPhase 1/2Boston Children's HospitalNCT04263831Written as Interleukin-2 (aldesleukin).
- Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.Not yet recruitingPhase 1/2Assistance Publique - Hôpitaux de ParisNCT07697118Written as ILT-101
- A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic MelanomaNot yet recruitingPhase 2East Metropolitan Health Service, AustraliaNCT07651618Written as Aldesleukin
- Use of Low Doses of Interleukin-2 in Autism Spectrum DisordersNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07589842Written as ILT-101 ld-(IL2)
- Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerRecruitingEarly Phase 1Emory UniversityNCT05493566Written as Aldesleukin
- Adding IL-2 to Tebentafusp to Eradicate Cancer ProgressionRecruitingPhase 1/2St Vincent's Hospital, SydneyNCT07063875Written as Aldesleukin
- IL-2 Plus Abatacept in FTDRecruitingPhase 1The Methodist Hospital Research InstituteNCT06395038Written as Abatacept plus Aldesleukin
- Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological TumorsRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06584006Written as Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections
- Immunotherapy for the Treatment of Advanced Solid TumorRecruitingPhase 1/2Tongji HospitalNCT03658785Written as Aldesleukin
- Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsTerminatedPhase 1/2Alaunos TherapeuticsNCT05194735Written as Aldesleukin (IL-2)
- Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2CompletedPhase 1City of Hope Medical CenterNCT01082926Written as aldesleukin
- Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT06253520Written as Aldesleukin
- Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV MelanomaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT01955460Written as Aldesleukin
See all 174 studies that test aldesleukin →
Given beside what is tested · 79 — aldesleukin is usual care or a partner of the new treatment
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT01174121Written as Aldesleukin
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsRecruitingPhase 1/2National Cancer Institute (NCI)NCT03190941Written as Aldesleukin
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03412877Written as Aldesleukin
- KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerRecruitingPhase 1Christian HinrichsNCT05483491Written as Aldesleukin
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersRecruitingPhase 2Christian HinrichsNCT05686226Written as Aldesleukin
- E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersRecruitingPhase 1/2Christian HinrichsNCT05639972Written as Aldesleukin
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2AstraZenecaNCT07681596Written as Aldesleukin
- A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.RecruitingPhase 1/2University of ChicagoNCT07389239Written as Aldesleukin
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerRecruitingPhase 1/2Aulos Bioscience, Inc.NCT05267626Written as Aldesleukin
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingPhase 2National Cancer Institute (NCI)NCT02621021Written as Aldesleukin
- A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast CancerRecruitingPhase 1University of Southern CaliforniaNCT05989828Written as Aldesleukin
- Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersRecruitingPhase 1/2Hadassah Medical OrganizationNCT05296564Written as Aldesleukin
- To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic MelanomaRecruitingPhase 1Inge Marie SvaneNCT06204991Written as Proleukin
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingPhase 3St. Anna KinderkrebsforschungNCT01704716Written as Aldesleukin
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01038778Written as Aldesleukin
- LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03449108Written as Aldesleukin
- TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCCCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06236425Written as Aldesleukin
- Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedPhase 3National Cancer Institute (NCI)NCT01041638Written as Aldesleukin
- Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 1Roswell Park Cancer InstituteNCT03017131Written as Aldesleukin
- E7 TCR T Cells for Human Papillomavirus-Associated CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT02858310Written as Aldesleukin
Showing 20 of 79.
As the comparator · 2 — what is tested is compared with aldesleukin
- Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural EffusionStatus unknownNot applicablePeking Union Medical CollegeNCT04131231Written as recombinant human interleukin-2(rhIL-2)
- Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...CompletedPhase 2National Cancer Institute (NCI)NCT01118091Written as Aldesleukin
What changed recently
From the registry's own updates since Oct 16, 2026.
Newly registered1
- Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney CancerNov 9, 2026NCT07925333
Codes
What other systems call aldesleukin · ClinicalTrials.gg INT003745
- MeSH (NLM) C082598aldesleukinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M89N0Q7EQRALDESLEUKINConfirmed FDA, NLM, Wikidata
- RxNorm 70223Confirmed FDA, Wikidata
- Wikidata Q20801763aldesleukinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1498AldesleukinOne source FDA
- DrugBank DB00041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C082598 | aldesleukin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M89N0Q7EQR | ALDESLEUKIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 70223 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20801763 | aldesleukin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1498 | Aldesleukin | One source FDA |
| DrugBank | DB00041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.